You respond as if 6 month review is the norm, it isn't. any drug that gets a review in six months is a big deal.
I believe that is the case with neop, that is a big deal.
I know you will have to get in the last word so I am awaiting your response, although I probably won't respond because this is getting tiring.
as I used to say to you on the genaera board responding to the dumbass questions, you are a better man than me with more patience. That is still true. The most important thing is that I have done great in the market over the last 5 years as I am sure you have, so I think we are both winners and do good fundamental analysis.
We don't have to agree on everything, but do you always have to have the last word.
Market Data 
Markets 
AI
